Screening Exclusively Open to NHF Annual Meeting Attendees - Documentary Features First Hemophiliac to Climb the Seven Summits
Octapharma has confirmed to invest Euro 21 million to build a new multi-function facility in Springe, Germany. The multi-function venue will have a new production line for human normal immunoglobulin panzyga®, alongside...
Octapharma USA Partners with GutMonkey To Provide Hemophilia Patients Life-Changing Adventure Experience
Leading X San Juan Islands Aims to Enhance Patient Self-Efficacy & Bleeding Disorder Management
HOBOKEN, N.J. (July 16, 2018) – Octapharma USA was the exclusive sponsor of the VWD Connect Foundation Conference, a four-day national program for patients with Type 3/severe Von Willebrand Disease (VWD), recently held at the PGA...
Toronto, Canada, June 25, 2018: – Octapharma announced today the launch of the Canadian PREVAIL (Immune Tolerance Induction in Hemophilia A Patients using wilate®) study for patients with Hemophilia A. The PREVAIL study will...
Octapharma announces approval of new Nuwiq® product strengths in Europe, increasing dosing flexibility for patients with haemophilia A
Lachen, Switzerland 18 June 2018: Octapharma announced today that the European Medicines Agency (EMA) has approved an extension of marketing authorisation for its human cell line-derived recombinant factor VIII (rFVIII)...
Octapharma share promising preclinical data for SubQ-8, a novel subcutaneous recombinant FVIII, at WFH 2018
Lachen, Switzerland 28 May 2018: Octapharma announced today that pre-clinical data for SubQ-8 were presented during a symposium at the recent World Federation of Hemophilia (WFH) 2018 World Congress in Glasgow, UK. SubQ-8,...